Sign in
CompletedNo phase

Pioglitazone for the Treatment of Alcohol Use Disorder

Key facts

Who runs it
VA Office of Research and Development
Where
Long Beach and Minneapolis, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
201 people enrolled
Started
17 Jul 2019
Ended
29 Mar 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Brief Behavioral Compliance Enhancement Treatment
Record updated
13 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • DSM-5 diagnosis of at least moderate alcohol use disorder using the SCID
  • A mean of six heavy drinking days per month for the 3-months prior to baseline
  • Drinking at least 14 drinks for men or 7 drinks for women, or more per week for the 4 weeks preceding the screening visit
  • Willingness to provide contact information to confirm study follow-up appointments
  • Ability to perform informed consent
  • Female subjects: a negative pregnancy test
  • Serum ALT < 3 times reference range
  • Stable psychiatric medication doses the month prior to baseline visit (antidepressant, antipsychotic, subjects may have changes in trazodone for sleep)

Who cannot take part

  • Taking medications known to have significant drug interactions with the study medication (CYP2C8 inhibitors or inducers, antihyperglycemic medications)
  • Currently being treated for AUD with a medication (naltrexone, naltrexone injectable, acamprosate, topiramate, disulfiram and gabapentin)
  • Current DSM-5 diagnosis of moderate to severe psychoactive substance use disorder (i.e. cocaine, opiates, methamphetamine) other than cannabis or nicotine
  • Medical conditions contraindicating pioglitazone pharmacotherapy (e.g., congestive heart failure, clinically significant edema, clinically significant liver disease, hypoglycemia, diabetes, history of bladder cancer)
  • Cognitive or physical impairment that precludes study participation
  • Currently and seriously suicidal (i.e., plan and intent)
  • Impending incarceration
  • Pregnant or planning to become pregnant during the course of the trial or nursing for female patients
  • Unwillingness to sign a written informed consent form
  • Unwillingness to use a barrier method of birth control during the study for female patients

Where in United States

  • VA Long Beach Healthcare System, Long Beach, CALong Beach, United States
  • Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, United States

About the trial

What the trial wants to find out

Alcohol Use Disorder (AUD) is common among Veterans but medication treatment is used infrequently and the impact of these treatments are small to moderate at best. Pioglitazone, a medication FDA approved for diabetes, has been shown in pre-clinical studies to reduce alcohol. The proposed study will test the efficacy of pioglitazone to reduce alcohol use in a double-blind placebo controlled trial. Investigators plan to compare pioglitazone to placebo in 200 Veterans who have an AUD and who are currently drinking alcohol at two Veterans Affairs Health Care Centers. The primary hypothesis is that Veterans with an AUD who are currently drinking alcohol will have a greater reduction in alcohol use following treatment with pioglitazone compared to those treated with placebo.

The 2 groups in the trial

  • PioglitazoneTreatment being tested

    Pioglitazone titrated to 45mg by mouth each day

    Treatment: Brief Behavioral Compliance Enhancement Treatment

  • PlaceboPlacebo, for comparison

    placebo, identical 45mg pill

    Treatment: Brief Behavioral Compliance Enhancement Treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Trial of Pioglitazone for the Treatment of Alcohol Use Disorder
Record updated
13 June 2025